Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange.
Two Mentors Who Shaped an Oncologist s Approach to Ovarian Cancer
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Glassdoor ranks H-E-B chairman Charles Butt in top CEO list
mysanantonio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mysanantonio.com Daily Mail and Mail on Sunday newspapers.
MD Anderson Cancer Center announces changed to COVID-19 policy
click2houston.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from click2houston.com Daily Mail and Mail on Sunday newspapers.